315-72-0
315-72-0
Chemical Structure
Opipramol
Synonym(s): Ensidon; G-33040
- CAS No.: 315-72-0
- Formula:C23H29N3O
- Molecular Weight:363.50
IUPAC Name: 2-(4-(3-(5H-dibenzo[b,f]azepin-5-yl)propyl)piperazin-1-yl)ethan-1-ol
InChIKey: YNZFUWZUGRBMHL-UHFFFAOYSA-N
SMILES: OCCN1CCN(CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1
Biological Activity: Opipramol (Ensidon) is an atypical tricyclic antidepressant (TCA). Opipramol acts primarily as a sigma (σ) receptor agonist and can potently interact with sigma recognition sites with a Ki value of 50 nM. Opipramol can be used for the research of generalized anxiety disorder (GAD)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Opipramol | 99.91% | Opipramol (Ensidon) is an atypical tricyclic antidepressant (TCA). Opipramol acts primarily as a sigma (σ) receptor agonist and can potently interact with sigma recognition sites with a Ki value of 50 nM. Opipramol can be used for the research of generalized anxiety disorder (GAD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Opipramol (Standard) | ≥98% | Opipramol (Standard) is the analytical standard of Opipramol. This product is intended for research and analytical applications. Opipramol (Ensidon) is an atypical tricyclic antidepressant (TCA). Opipramol acts primarily as a sigma (σ) receptor agonist and can potently interact with sigma recognition sites with a Ki value of 50 nM. Opipramol can be used for the research of generalized anxiety disorder (GAD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Opipramol-d4 | Opipramol-d4 is the deuterium labeled Opipramol. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. H J Möller, et al. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol. 2001 Feb;21(1):59-65. [Content Brief]
- [2]. T S Rao, et al. Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivo. Neuropharmacology. 1990 Dec;29(12):1191-7. [Content Brief]
